Catalyst

Slingshot members are tracking this event:

PMA filing for Opko (OPK) POC diagnostic test set for first half of 2017, with FDA application to follow

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
OPK

100%

Additional Information

Additional Relevant Details Link to catalyst regarding FDA application, study details
https://slingshotins...
Additional Relevant Details Update on Aug 8 2017: Clinical trials of Claros point-of-care (POC) prostate specific antigen (PSA) test completed and Premarket Approval (PMA) filing anticipated this fall.
http://investor.opko...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pma Filing, Fda Review, Poc Diagnostic Test